NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free ACET Stock Alerts $1.95 -0.05 (-2.50%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.88▼$2.0650-Day Range$2.00▼$3.4552-Week Range$1.10▼$7.53Volume946,977 shsAverage Volume1.75 million shsMarket Capitalization$136.81 millionP/E RatioN/ADividend YieldN/APrice Target$13.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Adicet Bio alerts: Email Address Adicet Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside597.4% Upside$13.60 Price TargetShort InterestBearish8.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 5 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.94) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector331st out of 946 stocksPharmaceutical Preparations Industry157th out of 433 stocks 3.3 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.60, Adicet Bio has a forecasted upside of 597.4% from its current price of $1.95.Amount of Analyst CoverageAdicet Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.07% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently increased by 19.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 2.5 News and Social Media Coverage News SentimentAdicet Bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adicet Bio this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat Follows14 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,500,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.29% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to grow in the coming year, from ($2.94) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Adicet Bio Stock (NASDAQ:ACET)Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.Read More ACET Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Short Interest UpdateMarch 14, 2024 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Rating Upgraded by StockNews.comMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 12, 2024 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Price Passes Above 200 Day Moving Average of $1.90March 11, 2024 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 5, 2024 | investorplace.com3 High-Risk Stocks That Could Pay Off in the MillionsFebruary 29, 2024 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | investorplace.com7 Top-Tier Penny Stocks for a Smart BetMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 19, 2024 | finance.yahoo.comACET Apr 2024 7.500 callFebruary 13, 2024 | msn.comJones upgrades Adicet to buy, cites upcoming catalystsFebruary 5, 2024 | finance.yahoo.comAdicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 25, 2024 | finance.yahoo.comAdicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesJanuary 23, 2024 | finance.yahoo.comAdicet Bio, Inc. Announces Pricing of Public OfferingJanuary 22, 2024 | markets.businessinsider.comAdicet Bio Commences Underwritten Public Offering Of Common StockJanuary 22, 2024 | finance.yahoo.comAdicet Bio, Inc. Announces Proposed Public OfferingJanuary 9, 2024 | msn.comAdicet Bio, Inc. (ACET) Upgraded to Buy: Here's WhyJanuary 9, 2024 | seekingalpha.comAdicet Bio: Clinical Updates In 2H 2024 Makes This A Must-WatchJanuary 7, 2024 | finance.yahoo.comGreat week for Adicet Bio, Inc. (NASDAQ:ACET) institutional investors after losing 71% over the previous yearJanuary 5, 2024 | ca.finance.yahoo.comACET Apr 2024 2.500 callJanuary 4, 2024 | msn.comAdicet Bio stock rallies 26% on pipeline, cash runway updatesJanuary 4, 2024 | finance.yahoo.comAdicet Provides Corporate Update and Highlights Strategic Priorities for 2024January 3, 2024 | businesswire.comAdicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate OutlookDecember 7, 2023 | morningstar.comAdicet Bio Inc Ordinary SharesNovember 16, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN) and Adicet Bio (ACET)November 10, 2023 | markets.businessinsider.comAdicet Bio: Buy Rating Driven by Strategic Overhaul and Promising Oncology DevelopmentsSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/19/2024Next Earnings (Estimated)3/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$13.60 High Stock Price Target$27.00 Low Stock Price Target$6.00 Potential Upside/Downside+597.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.82% Return on Assets-43.11% Debt Debt-to-Equity RatioN/A Current Ratio9.40 Quick Ratio9.40 Sales & Book Value Annual Sales$24.99 million Price / Sales5.47 Cash FlowN/A Price / Cash FlowN/A Book Value$6.82 per share Price / Book0.29Miscellaneous Outstanding Shares70,160,000Free Float49,465,000Market Cap$136.81 million OptionableOptionable Beta1.87 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 52)CPA, M.B.A., CEO, President & Director Comp: $899.58kDr. Blake Aftab Ph.D. (Age 43)Senior VP & Chief Scientific Officer Comp: $675.04kDr. Francesco Galimi M.D. (Age 56)Ph.D., Chief Medical Officer & Senior VP Comp: $680.37kMr. Brian Nicholas Harvey (Age 63)Chief Financial Officer Comp: $596.79kDr. Donald Healey Ph.D. (Age 62)Chief Technology Officer Ms. Amy LockeHead of Human ResourcesDr. Nancy L. Boman M.D.Ph.D., Senior VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsProQR TherapeuticsNASDAQ:PRQRRelmada TherapeuticsNASDAQ:RLMDKaryopharm TherapeuticsNASDAQ:KPTIAtossa TherapeuticsNASDAQ:ATOSNektar TherapeuticsNASDAQ:NKTRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 12,689 shares on 3/11/2024Ownership: 2.402%Goldman Sachs Group Inc.Sold 30,898 shares on 3/1/2024Ownership: 0.041%GSA Capital Partners LLPSold 121,494 shares on 2/16/2024Ownership: 0.029%Occudo Quantitative Strategies LPSold 4,851 shares on 2/15/2024Ownership: 0.109%Citadel Advisors LLCSold 3,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACET Stock Analysis - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price target for 2024? 7 equities research analysts have issued 1-year price objectives for Adicet Bio's shares. Their ACET share price targets range from $6.00 to $27.00. On average, they predict the company's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 597.4% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2024? Adicet Bio's stock was trading at $1.89 at the beginning of 2024. Since then, ACET shares have increased by 3.2% and is now trading at $1.95. View the best growth stocks for 2024 here. Are investors shorting Adicet Bio? Adicet Bio saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 5,660,000 shares, an increase of 19.2% from the February 14th total of 4,750,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio is currently 3.7 days. View Adicet Bio's Short Interest. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) posted its earnings results on Wednesday, November, 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.44). The company had revenue of $3.43 million for the quarter, compared to the consensus estimate of $4.65 million. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). Who are Adicet Bio's major shareholders? Adicet Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (5.89%), Vanguard Group Inc. (2.40%), Vanguard Group Inc. (2.40%), Norges Bank (0.61%), Nuveen Asset Management LLC (0.28%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott, Orbimed Advisors Llc and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACET) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.